🇨🇭 NOVN.SW — Novartis AG

Healthcare Mantener
← Volver

Precio actual

125,46 CHF

Máx. histórico

132,68

4 días

Split 40:1 del 07/05/2001

Caída desde máximo

-5,44%

Rango 52 semanas

96,03 – 132,68

Variación hoy

-3,18%

Cierre anterior

129,58

Rango de hoy

124,60 – 127,22

Volumen hoy

3.116.259

Información
Nombre completo
Novartis AG
Divisa
CHF
Mercado
Swiss
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
75.267
PER ⓘ
23,32 (puede no estar actualizado)
Dividend yield
2,86% (puede no estar actualizado)
Precio objetivo analistas
125,45 CHF (puede no estar actualizado)
Primera cotización
03/04/1995
Precio actualizado
hace 13 horas
Sobre la empresa

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Dividendos repartidos Total últimos 12 meses: 3,7000 CHF · Yield: 2,95%
Fecha de pago Importe por participación
10/03/2026 3,7000 CHF
11/03/2025 3,5000 CHF
07/03/2024 3,3000 CHF
09/03/2023 3,2000 CHF
08/03/2022 3,1000 CHF
04/03/2021 3,0000 CHF
03/03/2020 2,9500 CHF
04/03/2019 2,8500 CHF
06/03/2018 2,8000 CHF
02/03/2017 2,7500 CHF
25/02/2016 2,7000 CHF
03/03/2015 2,6000 CHF
27/02/2014 2,4500 CHF
26/02/2013 2,3000 CHF
27/02/2012 2,2500 CHF
Splits Registrados en el histórico de precios
Fecha Ratio
07/05/2001 40:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
14/06/2012 43,02 43,06 42,69 42,77 -0,58% 0,88% 5.363.377
13/06/2012 42,56 43,02 42,56 43,02 +1,08% 1,08% 8.080.875
12/06/2012 42,02 42,69 42,02 42,56 +1,09% 1,60% 5.087.722
11/06/2012 42,52 42,60 41,98 42,10 -0,10% 1,48% 4.143.645
08/06/2012 41,89 42,23 41,77 42,14 +0,60% 1,10% 3.113.476
07/06/2012 41,77 41,98 41,68 41,89 -0,10% 0,70% 5.036.611
06/06/2012 41,51 42,02 41,41 41,93 +1,05% 1,47% 6.005.561
05/06/2012 41,67 41,68 41,44 41,50 +0,08% 0,58% 3.012.515
04/06/2012 41,82 41,82 41,41 41,46 -0,96% 1,00% 3.312.135
01/06/2012 42,27 42,31 41,77 41,87 -0,95% 1,29% 8.132.495
31/05/2012 42,56 42,69 42,14 42,27 -0,20% 1,28% 9.455.548
30/05/2012 42,06 42,69 41,98 42,35 +0,70% 1,69% 7.697.608
29/05/2012 42,02 42,27 41,89 42,06 +0,56% 0,90% 3.472.031
25/05/2012 41,53 41,93 41,46 41,82 +0,89% 1,15% 4.710.536
24/05/2012 41,12 41,60 40,96 41,46 +0,88% 1,55% 3.391.747
23/05/2012 41,47 41,81 41,04 41,10 -1,07% 1,86% 4.465.562
22/05/2012 41,01 41,54 40,93 41,54 +1,60% 1,49% 5.213.992
21/05/2012 40,93 41,10 40,64 40,89 -0,20% 1,11% 4.536.296
18/05/2012 40,47 41,26 40,46 40,97 -0,41% 1,99% 9.205.995
16/05/2012 41,10 41,31 40,89 41,14 -0,28% 1,04% 4.539.181
15/05/2012 41,40 41,40 41,10 41,26 -0,26% 0,73% 2.549.413
14/05/2012 41,39 41,57 41,11 41,36 -0,70% 1,09% 5.130.370
11/05/2012 41,14 41,66 41,05 41,66 +1,16% 1,47% 4.216.620
10/05/2012 41,35 41,45 40,71 41,18 -0,55% 1,78% 5.408.533
09/05/2012 41,72 41,76 41,17 41,41 -0,86% 1,41% 5.457.532
08/05/2012 41,89 41,93 41,63 41,77 -0,30% 0,72% 4.323.096
07/05/2012 41,71 42,02 41,49 41,89 +0,58% 1,27% 5.077.140
04/05/2012 41,52 41,98 41,47 41,65 +0,22% 1,21% 4.619.892
03/05/2012 41,83 42,02 41,36 41,56 -0,24% 1,58% 5.288.416
02/05/2012 42,27 42,31 41,54 41,66 -0,66% 1,82% 6.192.050